Evidence map›Paper›PMID 32524295›Full record

ArticleMedical oncology (Northwood, London, England)2020

Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer.

D K Reyes, S P Rowe, E M Schaeffer, M E Allaf, A E Ross, C P Pavlovich, C Deville, P T Tran, K J Pienta

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

D K ReyesThe James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. dreyes@jhmi.edu.ORCID http://orcid.org/0000-0001-7350-3934
S P RoweThe James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
E M SchaefferDepartment of Urology, Feinberg School of Medicine, Northwestern University, Evanston, IL, USA.
M E AllafThe James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
A E RossTexas Urology Specialists, Mary Crowley Cancer Research, Dallas, TX, USA.
C P PavlovichThe James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
C DevilleDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
P T TranThe James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
K J PientaThe James Buchanan Brady Urologic Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Johns Hopkins University · USMary Crowley Cancer Research Center · USNorthwestern University · US

Funding

Tumor microvesicle-mediated modulation of the bone microenvironmentP01CA093900 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KELLER, EVAN T · 2004 to 2024
$29.6M
TRANS_NETWORK PROJECTSU54CA143803 · NCI · PRINCETON UNIVERSITY · PI AUSTIN, ROBERT H. · 2009 to 2013
$14.2M
Mechanisms That Regulate Dormancy of Disseminated Tumor Cells in the Bone MarrowU54CA163124 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHIOZAWA, YUSUKE · 2011 to 2015
$3.0M
Reactive Stroma and Tumor Associated Macrophages in Prostate Cancer ProgressionU01CA143055 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI PIENTA, KENNETH J., ROWLEY, DAVID R · 2010 to 2014
$2.7M
National Cancer Institute CA093900National Cancer Institute CA143055National Cancer Institute CA163124National Cancer Institute U54CA143803
6 · The paper itself

Abstract

To evaluate the outcomes of total eradication therapy (TET), designed to eradicate all sites of visible cancer and micrometastases, in men with newly diagnosed oligometastatic prostate cancer (OMPCa). Men with ≤ 5 sites of metastases were enrolled in a prospective registry study, underwent neoadjuvant chemohormonal therapy, followed by radical prostatectomy, adjuvant radiation (RT) to prostate bed/pelvis, stereotactic body radiation therapy (SBRT) to oligometastases, and adjuvant hormonal therapy (HT). When possible, the prostate-specific membrane antigen targeted

Indexed as

AnilidesAntigens, SurfaceAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantCombined Modality TherapyDexamethasoneDisease-Free SurvivalDocetaxelGlutamate Carboxypeptidase IIGonadotropin-Releasing HormoneHumansKallikreinsMaleMiddle AgedNeoadjuvant TherapyNeoplasm MetastasisAnilidesAntigens, SurfacebicalutamideDexamethasoneDocetaxelFOLH1 protein, humanGlutamate Carboxypeptidase IIGonadotropin-Releasing HormoneKallikreinsKLK3 protein, humanNitrilesProstate-Specific AntigenTosyl CompoundsOligometastasesOligometastatic prostate cancerTotal eradication therapy

Identifiers

PMID32524295
PMCPMC7286864
OpenAlexW3033626615

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.